Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cefuroxime Sodium

FDA-approved product (injectable, injection), marketed as Cefuroxime And Dextrose In Duplex Container, Cefuroxime Sodium, Cefuroxime Sodium In Plastic Container and 4 more.

Registered studies
50+
Lab records
17
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Cefuroxime Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Eye infection
  • Infection
  • Pneumonia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Second-generation cephalosporins; Antibiotics
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DC02; WHO ATC S01AA27

Repurposing investigation

Cefuroxime Sodium is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA94.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli77.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae20.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis46.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 6 of 6 lab records
  • E. coli: measured active in 2 of 2 lab records
  • K. pneumoniae: measured active in 1 of 9 lab records
Open Cefuroxime Sodium in ChEMBL Registered studies below
Show the 17 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cefuroxime Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Multi-center Clinical Study of Drug Antibody and Precision Transfusion in China

    NCT05606302 · start 2021-10-01

    Registered record
    Registry ID
    NCT05606302
    Conditions
    Drug-specific Antibodies
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2021-10-01
    Completion
    2023-12
    Enrolment
    14,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug-specific Antibodies
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Cefuroxime Resistance in Pyelonephritis

    NCT04616352 · start 2020-12-26

    Registered record
    Registry ID
    NCT04616352
    Conditions
    Urinary Tract Infections
    Interventions
    Resistance to cefuroxime
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-12-26
    Completion
    2021-07-30
    Enrolment
    973

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections
    InterventionResistance to cefuroxime
    PhaseNot recorded
    Registry statusCompleted

  • Qingfei Granule for the Treatment of the Pediatric Acute Upper Respiratory Tract Infection With Bacterial Infection

    NCT04479657 · start 2020-10-17

    Registered record
    Registry ID
    NCT04479657
    Conditions
    Upper Respiratory Tract Infection; Bacterial Infection; Chinese Medicine; Pediatric Acute Upper Respiratory Tract Infection
    Interventions
    QingFei Granule; Cefuroxime
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Unknown
    Start
    2020-10-17
    Completion
    2024-06
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUpper Respiratory Tract Infection; Bacterial Infection; Chinese Medicine; Pediatric Acute Upper Respiratory Tract Infection
    InterventionQingFei Granule; Cefuroxime
    PhaseEarly phase 1
    Registry statusUnknown

  • Pharmacokinetics of Amikacin and Cefuroxime in Critically Ill Patients.

    NCT04470973 · start 2020-07-15

    Registered record
    Registry ID
    NCT04470973
    Conditions
    Sepsis; Septic Shock; Infection, Bacterial; Critically Ill
    Interventions
    Cefuroxime; Amikacin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2020-07-15
    Completion
    2023-12-15
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis; Septic Shock; Infection, Bacterial; Critically Ill
    InterventionCefuroxime; Amikacin
    PhaseNot recorded
    Registry statusUnknown

  • Single Dose Cefepime Versus Cefuroxime Plus Metronidazole as a Prophylactic Antibiotic During Emergency Intrapartum Cesarean Section

    NCT04009772 · start 2019-07-01

    Registered record
    Registry ID
    NCT04009772
    Conditions
    Emergency Cesarean Section; Infection Wound
    Interventions
    Cefepime; Cefuroxime plus Metronidazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2019-07-01
    Completion
    2020-03-01
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEmergency Cesarean Section; Infection Wound
    InterventionCefepime; Cefuroxime plus Metronidazole
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Effect of Topical Sinonasal Antibiotics

    NCT03935828 · start 2019-06

    Registered record
    Registry ID
    NCT03935828
    Conditions
    Chronic Rhinosinusitis (Diagnosis); Antibiotic Side Effect
    Interventions
    Oral versus topical antibioitics
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2019-06
    Completion
    2021-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Rhinosinusitis (Diagnosis); Antibiotic Side Effect
    InterventionOral versus topical antibioitics
    PhasePhase 2
    Registry statusWithdrawn

  • Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions

    NCT03014687 · start 2017-07-01

    Registered record
    Registry ID
    NCT03014687
    Conditions
    Antibiotics; Pituitary Adenoma
    Interventions
    Placebo; Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2017-07-01
    Completion
    2019-07
    Enrolment
    116

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntibiotics; Pituitary Adenoma
    InterventionPlacebo; Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
    PhasePhase 4
    Registry statusRecruiting

  • The Clinical Trial of Cefuroxime Axetil Dispersible Tablets

    NCT03020940 · start 2017-01

    Registered record
    Registry ID
    NCT03020940
    Conditions
    Infectious Disease
    Interventions
    Cefuroxime Axetil Dispersible Tablets
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2017-01
    Completion
    2019-11
    Enrolment
    100,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfectious Disease
    InterventionCefuroxime Axetil Dispersible Tablets
    PhaseNot recorded
    Registry statusUnknown

  • Study on Reduced Antibiotic Treatment vs Broad Spectrum Betalactam in Patients With Bacteremia by Enterobacteriaceae

    NCT02795949 · start 2016-10

    Registered record
    Registry ID
    NCT02795949
    Conditions
    Enterobacteriaceae Infections
    Interventions
    Antipseudomonal beta-lactam antibiotic; De-escalation(short-spectrum antibiotic)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-10
    Completion
    2020-01
    Enrolment
    344

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEnterobacteriaceae Infections
    InterventionAntipseudomonal beta-lactam antibiotic; De-escalation(short-spectrum antibiotic)
    PhasePhase 3
    Registry statusCompleted

  • Comparison of Two Antibiotic Prophylactic Protocols in Preterm Premature Rupture of the Membranes

    NCT02819570 · start 2015-11

    Registered record
    Registry ID
    NCT02819570
    Conditions
    Premature Rupture of Membrane
    Interventions
    I.V cefuroxime 750 mg*3/d for 2 days; I.V ampicillin 2 gram x4/d for 2 days; P.O cefuroxime 500 mgx2/d for 5 days; P.O roxithromycin 150 mg*2/d for 7 days; P.O moxypen 500 mgx3/d for 5 days
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2015-11
    Completion
    2017-12
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPremature Rupture of Membrane
    InterventionI.V cefuroxime 750 mg*3/d for 2 days; I.V ampicillin 2 gram x4/d for 2 days; P.O cefuroxime 500 mgx2/d for 5 days; P.O roxithromycin 150 mg*2/d for 7 days +1 more
    PhasePhase 4
    Registry statusUnknown

  • RCT of Postoperative Infections Following Caesarean Section Infections Following Caesarean Section

    NCT02009098 · start 2014-10

    Registered record
    Registry ID
    NCT02009098
    Conditions
    Postoperative Infection
    Interventions
    Cefuroxime
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2014-10
    Completion
    2016-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Infection
    InterventionCefuroxime
    PhasePhase 4
    Registry statusWithdrawn

  • Antibiotics and Gut Microbiota Among Newborn Infants

    NCT02072798 · start 2014-02

    Registered record
    Registry ID
    NCT02072798
    Conditions
    Surgical Wound Infection; Infection; Cesarean Section; Complications; Cesarean Section
    Interventions
    Cefuroxime
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-02
    Completion
    2014-08
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSurgical Wound Infection; Infection; Cesarean Section; Complications +1 more
    InterventionCefuroxime
    PhasePhase 4
    Registry statusCompleted

  • Role of Emotional Freedom Techniques in Reducing Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy

    NCT02169856 · start 2013-07

    Registered record
    Registry ID
    NCT02169856
    Conditions
    Postoperative Nausea and Vomiting
    Interventions
    EFTs (emotional freedom techniques); Tab. Midazolam 7.5 mg; Inj. Midazolam 0.7mg/kg; Inj. Propofol 2.5mg/kg; Inj. Atracurium 0.5 mg/kg; Sevoflurane 2.5 vol %; Inj. Cefuroxime 1.5 g IV; Drug: Inj. Ketorolac 30 mg IV; Inj. Zantac 50mg IV
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-07
    Completion
    2014-02
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Nausea and Vomiting
    InterventionEFTs (emotional freedom techniques); Tab. Midazolam 7.5 mg; Inj. Midazolam 0.7mg/kg; Inj. Propofol 2.5mg/kg +5 more
    PhaseNot applicable
    Registry statusCompleted

  • Randomized Controlled Trial to Evaluate the Optimal Timing of Surgical Antimicrobial Prophylaxis

    NCT01790529 · start 2013-02

    Registered record
    Registry ID
    NCT01790529
    Conditions
    Surgical Site Infection
    Interventions
    Early administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in anesthetic room (75 to 30 minutes prior to skin incision); Late administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in the operating theatre (within 30 minutes prior to skin incision)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-02
    Completion
    2016-09
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSurgical Site Infection
    InterventionEarly administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in anesthetic room (75 to 30 minutes prior to skin incision); Late administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in the operating theatre (within 30 minutes prior to skin incision)
    PhasePhase 4
    Registry statusCompleted

  • Does Sugared or Sugar Free Chewing Gum Reduces Postoperative Ileus After Laparoscopic Cholecystectomy

    NCT02162134 · start 2013-01

    Registered record
    Registry ID
    NCT02162134
    Conditions
    Postoperative Ileus.
    Interventions
    sugar free chewing gum; sugared chewing gum; Tab. Midazolam 7.5 mg; Inj. Midazolam 0.7mg/kg 45 min before surgery; Inj. Propofol 2.5mg/kg; Inj. Atracurium 0.5 mg/kg; Sevoflurane 2.5 vol %; Inj. Cefuroxime 1.5 g IV; Inj. Ketorolac 30 mg IV; Inj. Zantac 50mg IV
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-01
    Completion
    2014-02
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Ileus.
    Interventionsugar free chewing gum; sugared chewing gum; Tab. Midazolam 7.5 mg; Inj. Midazolam 0.7mg/kg 45 min before surgery +6 more
    PhaseNot applicable
    Registry statusCompleted